By combining SARS-CoV epitope, a tumor unrelated antigenic fragment, with CEA, we finally demonstrated this could be a promising anti-cancer strategy through effectively increasing both Th1 and Th2 cytokines and decreasing tumor volume. The gene discussed is CEACAM5; the disease is neoplasm.